Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing capacity ramp-ups, antibody pipeline milestones, and cash-burn assumptions make Twist Bioscience’s SEC disclosures uniquely complex. Locating gene-synthesis revenue mix in the Twist Bioscience annual report 10-K simplified filing or tracing collaboration updates buried in an 8-K often means scrolling through hundreds of pages. Stock Titan solves this pain point by turning dense biotechnology jargon into concise insights, giving you twist bioscience SEC filings explained simply without losing critical detail.
Our AI reads every document the instant it hits EDGAR, delivering Twist Bioscience Form 4 insider transactions real-time, red-flagging risk-factor changes, and extracting segment metrics into dashboards. Whether you’re searching for a twist bioscience quarterly earnings report 10-Q filing, a sudden twist bioscience 8-K material events explained, or the latest twist bioscience proxy statement executive compensation tables, the platform highlights exactly where the numbers live and what they mean. Smart tags link cash-flow shifts to R&D spending so you can perform twist bioscience earnings report filing analysis in minutes, not hours.
Need to monitor management moves before the next capital raise? Track every twist bioscience insider trading Form 4 transactions alert or dive deeper into twist bioscience executive stock transactions Form 4 to spot buying trends. From cost-of-goods disclosures that impact gross margin to litigation notes that could reshape IP value, our expert commentary keeps you ahead. If you’re focused on understanding Twist Bioscience SEC documents with AI, start here—comprehensive coverage, real-time updates, and plain-English explanations for every filing type.
Twist Bioscience Corp (TWST) reported an insider transaction by President and COO Patrick John Finn. On 11/03/2025, he disposed of 2,755 shares of common stock at a price of $32.0794 per share.
The filing states these shares were sold to satisfy tax withholding obligations related to the vesting of Restricted Stock Units under the company’s equity incentive plans, a mandated “sell to cover” and not a discretionary trade by the reporting person. Following the transaction, he directly beneficially owned 265,919 shares.
Twist Bioscience (TWST) insider Paula Green, SVP of Human Resources, reported a transaction on 11/03/2025. She sold 1,084 shares of common stock at $32.0794 per share. According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon the vesting of Restricted Stock Units and did not represent a discretionary trade. Following the transaction, she beneficially owns 142,187 shares directly.
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a Form 4 transaction: she sold 4,887 shares of common stock on 11/03/2025 at $32.0794 per share.
According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon RSU vesting, and not a discretionary trade. Following the transaction, she beneficially owns 733,922 shares directly.
She also holds employee stock options, including 266,539 at $26.66 expiring 11/18/2028 and 150,879 at $8.82 expiring 09/28/2027.
Twist Bioscience (TWST) disclosed an insider transaction by its Chief Accounting Officer, Robert F. Werner. On 11/03/2025, he sold 160 shares of common stock at $32.0794 in a mandated sell-to-cover to satisfy tax withholding arising from the vesting of restricted stock units under the company’s equity plan. Following the transaction, his beneficial ownership stood at 50,870 shares.
Twist Bioscience (TWST) filed a Form 4 reporting an insider tax-related sale. On 10/30/2025, a company officer executed a mandated "sell-to-cover" of 6,515 shares of common stock at $31.4443 per share to satisfy tax withholding tied to the vesting of Performance Stock Units. The filing notes these were not discretionary trades.
Following the transaction, the reporting person directly owned 121,713 shares. The insider is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary.
Twist Bioscience (TWST) reported an insider transaction by President and COO Patrick John Finn. On 10/30/2025, he sold 17,606 shares of common stock at $31.4443 per share, coded “S.” The filing states these shares were sold solely to cover tax withholding triggered by the vesting of Performance Stock Units under a mandated “sell to cover” election in the company’s equity plans, indicating they were not discretionary trades.
Following the transaction, Finn beneficially owns 268,674 shares, held directly.
Twist Bioscience (TWST) reported an insider transaction by its SVP of Human Resources, Paula Green. On 10/30/2025, she sold 6,920 shares of common stock (transaction code S) at $31.4443 per share. The filing states these shares were sold to satisfy tax withholding obligations from vesting Performance Stock Units via a mandated “sell to cover,” indicating they were not discretionary trades. Following the transaction, she beneficially owned 143,271 shares, held directly.
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a transaction on 10/30/2025: the disposition of 31,379 shares of common stock at $31.4443 per share. The filing states these shares were sold to cover tax withholding tied to the vesting of performance stock units, pursuant to the company’s equity plan “sell to cover” election, and were not discretionary trades.
Following the transaction, Leproust beneficially owns 738,809 common shares directly. Derivative holdings listed include employee stock options, such as 150,879 options at an exercise price of $8.82 and 266,539 options at $26.66, among others with varying vesting and expiration terms.
Twist Bioscience (TWST) reported an insider transaction by its Chief Financial Officer, Adam Laponis. On 10/30/2025, the CFO sold 5,517 shares of common stock at $31.4443 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Performance Stock Units and were executed as a mandated “sell to cover,” not a discretionary trade.
Following the transaction, the reporting person beneficially owns 111,008 shares directly.
Twist Bioscience (TWST) insider transaction: the Chief Accounting Officer reported a sale of 1,016 shares of common stock on 10/30/2025 at a price of $31.4443 per share. The filing states the sale was a mandated “sell to cover” to satisfy tax withholding obligations tied to the vesting of Performance Stock Units, and not a discretionary trade. Following the transaction, the reporting person beneficially owned 51,030 shares, held directly.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
